5-HT2A and 5-HT2C receptor stimulation are differentially involved in the cortical dopamine efflux-Studied in 5-HT 2A and 5-HT2C genetic mutant mice

European Journal of Pharmacology

Volumn 652, Issue 1-3, 2011, Pages 40-45

  Huang, Mei ^a   Dai, Jin ^a   Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 HT2A 2C receptor agonist; Cortex; Dopamine; Knockout mice; Microdialysis

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 6 CHLORO 2 (1 PIPERAZINYL)PYRAZINE; DOPAMINE; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATECHOLAMINE UPTAKE; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DRUG MECHANISM; KNOCKOUT MOUSE; MALE; MICRODIALYSIS; MOUSE; MOUSE MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR UPREGULATION; WILD TYPE;

ANIMALS; CEREBRAL CORTEX; DOPAMINE; HALLUCINATIONS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, MUTANT STRAINS; MICRODIALYSIS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN RECEPTOR AGONISTS;

EID: 78650923172     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.10.094     Document Type: Article

References (74)

1. C. Acuña-Castillo, C. Villalobos, P.R. Moya, P. Sáez, B.K. Cassels, and J.P. Huidobro-Toro Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT(2A) and 5-HT(2C) receptors Br. J. Pharmacol. 136 2002 510 519
2. G.K. Aghajanian, and G.J. Marek Serotonin and hallucinogens Neuropsychopharmacology 21 1999 16S 23S
3. K.D. Alex, and E.A. Pehek Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission Pharmacol. Ther. 113 2007 296 320
4. K.D. Alex, G.J. Yavanian, H.G. McFarlane, C.P. Pluto, and E.A. Pehek Modulation of dopamine release by striatal 5-HT2C receptors Synapse 55 2005 242 251
5. V.J. Aloyo, K.A. Berg, U. Spampinato, W.P. Clarke, and J.A. Harvey Current status of inverse agonism at serotonin(2A) (5-HT2A) and 5-HT(2C) receptors Pharmacol. Ther. 121 2009 160 173
6. J.C. Béïque, M. Imad, L. Mladenovic, J.A. Gingrich, and R. Andrade Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex Proc. Natl. Acad. Sci. U S A. 104 2007 9870 9875
7. K.A. Berg, J.A. Harvey, U. Spampinato, and W.P. Clarke Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors Trends Pharmacol, Sci. 26 2005 625 630
8. C. Bishop, J.L. Tessmer, T. Ullrich, K.C. Rice, and P.D. Walker Serotonin 5-HT2A receptors underlie increased motor behaviors induced in dopamine-depleted rats by intrastriatal 5-HT2A/2C agonism J. Pharmacol. Exp. Ther. 310 2004 687 694
9. L.J. Boothman, K.A. Allers, K. Rasmussen, and T. Sharp Evidence that central 5-HT2A and 5-HT2B/C receptors regulate 5-HT cell firing in the dorsal raphe nucleus of the anaesthetised rat Br. J. Pharmacol. 139 2003 998 1004
10. A. Bortolozzi, M. Amargós-Bosch, A. Adell, L. Díaz-Mataix, J. Serrats, S. Pons, and F. Artigas In vivo modulation of 5-hydroxytryptamine release in mouse prefrontal cortex by local 5-HT(2A) receptors: effect of antipsychotic drugs Eur. J. Neurosci. 18 2003 1235 1246
11. A. Bortolozzi, M. Amargós-Bosch, M. Toth, F. Artigas, and A. Adell In vivo efflux of serotonin in the dorsal raphe nucleus of 5-HT1A receptor knockout mice J. Neurochem. 88 2004 1373 1379
12. A. Bortolozzi, L. Díaz-Mataix, M.C. Scorza, P. Celada, and F. Artigas The activation of 5-HT2A receptors in prefrontal cortex enhances dopaminergic activity J. Neurochem. 95 2005 1597 1607
13. A. Bortolozzi, L. Díaz-Mataix, M. Toth, P. Celada, and F. Artigas In vivo actions of aripiprazole on serotoninergic and dopaminergic system in rodent brain Psychopharmacology 191 2007 745 758
14. F.P. Bymaster, D.O. Calligaro, J.F. Falcone, R.D. Marsh, N.A. Moore, N.C. Tye, P. Seeman, and D.T. Wong Radioreceptor binding profile of the atypical antipsychotic olanzapine Neuropsychopharmacology 14 1996 87 96
15. A. Castañé, F. Artigas, and A. Bortolozzi The absence of 5-HT(1A) receptors has minor effects on dopamine but not serotonin release evoked by MK-801 in mice prefrontal cortex Psychopharmacology (Berl) 200 2008 281 290
16. P. Celada, M.V. Puig, L. Díaz-Mataix, and F. Artigas The hallucinogen DOI reduces low-frequency oscillations in rat prefrontal cortex: reversal by antipsychotic drugs Biol. Psychiatry 64 2008 392 400
17. E. Chojnacka-Wojcik, and A. Klodzinska Involvement of 5-hydroxytryptamine 2A (5-HT2A) receptors in the mediation of the discriminative stimulus properties of (+/-) DOI in rats Pol. J. Pharmacol. 49 1997 299 304
18. T.I. Cremers, M. Giorgetti, F.J. Bosker, S. Hogg, J. Arnt, A. Mork, G. Honig, K.P. Bogeso, B.H. Westerink, H. den Boer, H.V. Wikstrom, and L.H. Tecott Inactivation of 5-HT(2C) receptors potentiates consequences of serotonin reuptake blockade Neuropsychopharmacology 29 2004 1782 1789
19. G.L. Dalton, M.D. Lee, G.A. Kennett, C.T. Dourish, and P.G. Clifton mCPP-induced hyperactivity in 5-HT2C receptor mutant mice is mediated by activation of multiple 5-HT receptor subtypes Neuropharmacology 46 2004 663 671
20. G. Di Giovanni, V. Di Matteo, M. Di Mascio, and E. Esposito Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study Synapse 35 2000 53 61
21. G. Di Giovanni, V. Di Matteo, M. Pierucci, A. Benigno, and E. Esposito Central serotonin2C receptor: from physiology to pathology Curr, Top Med. Chem. 6 2006 1909 1925
22. L. Díaz-Mataix, M.C. Scorza, A. Bortolozzi, M. Toth, P. Celada, and F. Artigas Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action J. Neurosci. 25 2005 10,831 10,843
23. J. Dunlop, A.L. Sabb, H. Mazandarani, J. Zhang, S. Kalgaonker, E. Shukhina, S. Sukoff, R.L. Vogel, G. Stack, L. Schechter, B.L. Harrison, and S. Rosenzweig-Lipson WAY-163909 [(7bR, 10aR)-1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta-[b][1, 4]diazepino[6, 7, 1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity J. Pharmacol. Exp. Ther. 313 2005 862 869
24. J. Dunlop, K.L. Marquis, H.K. Lim, L. Leung, J. Kao, C. Cheesman, and S. Rosenzweig-Lipson Pharmacological profile of the 5-HY2C receptor agonist WAY-163909: therapeutic potential in multiple indications CNS Drug Rev. 12 2006 167 177
25. W.E. Fantegrossi, K.S. Murnane, and C.J. Reissig The behavioral pharmacology of hallucinogens Biol. Pharmacol. 75 2008 17 33
26. D. Fiorella, R.A. Rabin, and J.C. Winter The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. I: antagonist correlation analysis Psychopharmacology (Berl) 121 1995 347 356
27. D. Fiorella, R.A. Rabin, and J.C. Winter Role of 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. II: reassessment of LSD false positives Psychopharmacology (Berl) 121 1995 357 363
28. D. Fiorella, R.A. Rabin, and J.C. Winter The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of m-chlorophenylpiperazine Psychopharmacology (Berl) 119 1995 222 230
29. J.C. Gewirtz, and G.J. Marek Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors Neuropsychopharmacology 23 2000 569 576
30. S.D. Gleason, V.L. Lucaites, H.E. Shannon, D.L. Nelson, and J.D. Leander m-CPP hypolocomotion is selectively antagonized by compounds with high affinity for 5-HT2C receptors but not 5-HT2A or 5-HT2B receptors Behav. Pharmacol. 12 2001 613 620
31. A. Gobert, and M.J. Millan Serotonin (5-HT)2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats Neuropharmacology 38 1999 315 317
32. A. Gobert, J.M. Rivet, F. Lejeune, A. Newman-Tancredi, A. Adhumeau-Auclair, J.P. Nicolas, L. Cistarelli, C. Melon, and M.J. Millan Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat Synapse 36 2000 205 221
33. J. González-Maeso, T. Yuen, B.J. Ebersole, E. Wurmbach, A. Lira, M. Zhou, N. Weisstaub, R. Hen, J.A. Gingrich, and S.C. Sealfon Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex J. Neurosci. 23 2003 8836 8843
34. J. González-Maeso, N.V. Weisstaub, M. Zhou, P. Chan, L. Ivic, R. Ang, A. Lira, M. Bradley-Moore, Y. Ge, Q. Zhou, S.C. Sealfon, and J.A. Gingrich Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior Neuron 53 2007 439 452
35. J. González-Maeso, R.L. Ang, T. Yuen, P. Chan, N.V. Weisstaub, J.F. López-Giménez, M. Zhou, Y. Okawa, L.F. Callado, G. Milligan, J.A. Gingrich, M. Filizola, J.J. Meana, and S.C. Sealfon Identification of a serotonin/glutamate receptor complex implicated in psychosis Nature 452 2008 93 97
36. L.K. Heisler, L. Zhou, P. Bajwa, J. Hsu, and L.H. Tecott Serotonin 5-HT2C receptors regulate anxiety-like behavior Genes, Brain Behav. 6 2007 491 496
37. J.M. Hitchcock, S. Lister, T.R. Fischer, and J.G. Wettstein Disruption of latent inhibition in the rat by the 5-HT2 agonist DOI: effects of MDL 100907, clozapine, risperidone and haloperidol Behav. Brain Res. 88 1997 43 49
38. J. Ichikawa, J. Dai, and H.Y. Meltzer DOI, a 5-HT2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release Brain Res. 907 2001 151 155
39. J. Ichikawa, H. Ishii, S. Bonaccorso, W.L. Fowler, I.A. O'Laughlin, and H.Y. Meltzer 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release J, Neurochem. 76 2001 1521 1531
40. R.L. Jakab, and P.S. Goldman-Rakic 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites Proc. Natl. Acad. Sci. U S A. 95 1998 735 740
41. A. Kłodzinska, M. Bijak, K. Tokarski, and A. Pilc Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice Pharmacol. Biochem. Behav. 73 2002 327 332
42. A.R. Knight, A. Misra, K. Quirk, K. Benwell, D. Revell, G. Kennett, and M. Bickerdike Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors Naunyn. Schmiedebergs Arch. Pharmacol. 370 2004 114 123
43. S. Kohnomi, K. Suemaru, H. Kawasaki, and H. Araki Effect of aripiprazole on 5-HT2 receptor-mediated wet-dog shake responses and disruption of prepulse inhibition in rats J. Pharmacol. Sci. 106 2008 645 650
44. Z. Li, J. Ichikawa, M. Huang, A.J. Prus, J. Dai, and H.Y. Meltzer ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens Psychopharmacology (Berl) 183 2005 144 153
45. J.F. Liégeois, J. Ichikawa, and H.Y. Meltzer 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner Brain Res. 947 2002 157 165
46. G. Lucas, and U. Spampinato Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum J. Neurochem. 74 2000 693 701
47. G.J. Marek, R.A. Wright, and D.D. Schoepp 5-Hydroxytryptamine2A (5-HT2A) receptor regulation in rat prefrontal cortex: interaction of a phenethylamine hallucinogen and the metabotropic glutamate2/3 receptor agonist LY354740 Neurosci. Lett. 403 2006 256 260
48. K.L. Marquis, A.L. Sabb, S.F. Logue, J.A. Brennan, M.J. Piesla, T.A. Comery, S.M. Grauer, C.R. Ashby Jr., H.Q. Nguyen, L.A. Dawson, J.E. Barrett, G. Stack, H.Y. Meltzer, B.L. Harrison, and S. Rosenzweig-Lipson WAY-163909 [(7bR, 10aR)-1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta-[b][1, 4]diazepino[6, 7, 1hi]indole]: a novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity Pharmacol. Exp. Ther. 320 2007 486 496
49. R. Martín-Ruiz, M.V. Puig, P. Celada, D.A. Shapiro, B.L. Roth, G. Mengod, and F. Artigas Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism J. Neurosci. 21 2001 9856 9866
50. H.Y. Meltzer, Z. Li, Y. Kaneda, and J. Ichikawa Serotonin receptors: their key role in drugs to treat schizophrenia Prog. Neuropsychopharmacol. Biol. Psychiatry. 27 2003 1159 1172
51. M.J. Millan, A. Dekeyne, and A. Gobert Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo Neuropharmacology 37 1998 953 955
52. J.M. Monti, and H. Jantos Effects of the serotonin 5-HT2A/2C receptor agonist DOI and of the selective 5-HT2A or 5-HT2C receptor antagonists EMD 281014 and SB-243213, respectively, on sleep and waking in the rat Eur. J. Pharmacol. 553 2006 163 170
53. D.L. Nelson, V.L. Lucaites, D.B. Wainscott, and R.A. Glennon Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors Naunyn. Schmiedebergs Arch. Pharmacol. 359 1999 1 6
54. B.A. Nic Dhonnchadha, M. Hascoët, P. Jolliet, and M. Bourin Evidence for a 5-HT2A receptor mode of action in the anxiolytic-like properties of DOI in mice Behav. Brain Res. 147 2003 175 184
55. D.E. Nichols Hallucinogens Pharmacol. Ther. 101 2 2004 131 181
56. L.H. Parsons, T.M. Kerr, and L.H. Tecott 5-HT1A receptor mutant mice exhibit enhanced tonic, stress-induced and fluoxetine-induced serotonergic neurotransmission J. Neuochem. 77 2001 606 617
57. G. Paxinos, and K.B.J. Franklin The Mouse Brain in Stereotaxic Coordinates 2004 Academic Press
58. E.A. Pehek, H.G. McFarlane, K. Maguschak, B. Price, and C.P. Pluto M100,907, a selective 5-HT(2A) antagonist, attenuates dopamine release in the rat medial prefrontal cortex Brain Res. 888 2001 51 59
59. E.A. Pehek, C. Nocjar, B.L. Roth, T.A. Byrd, and O.S. Mabrouk Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex Neuropsychopharmacology 31 2006 265 277
60. L. Pozzi, S. Acconcia, I. Ceglia, R.W. Invernizzi, and R. Samanin Stimulation of 5-hydroxytryptamine (5-HT(2C)) receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortex J. Neurochem. 82 2002 93 100
61. G.P. Reynolds Receptor mechanisms in the treatment of schizophrenia J. Psychopharmacol. 18 2004 340 345
62. B.A. Rocha, E.H. Goulding, L.E. O'Dell, A.N. Mead, N.G. Coufal, L.H. Parsons, and L.H. Tecott Enhanced locomotor, reinforcing, and neurochemical effects of cocaine in serotonin 5-hydroxytryptamine 2C receptor mutant mice J. Neurosci. 22 2002 10,039 10,045
63. S. Rosenzweig-Lipson, J. Dunlop, and K.L. Marquis 5-HT2C receptor agonists as an innovative approach for psychiatric disorders Drug News Perspect. 20 2007 565 571
64. L.E. Rueter, L.H. Tecott, and P. Blier In vivo electrophysiological examination of 5-HT2 responses in 5-HT2C receptor mutant mice Naunyn. Schmiedebergs Arch. Pharmacol. 361 2000 484 491
65. R. Schreiber, M. Brocco, and M.J. Millan Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone Eur. J. Pharmacol. 264 1994 99 102
66. J.L. Scruggs, S. Patel, M. Bubser, and A.Y. Deutch DOI-induced activation of the cortex: dependence on 5-HT2A heteroceptors on thalamocortical glutamatergic neurons J. Neurosci. 20 2000 8846 8852
67. J.L. Scruggs, D. Schmidt, and A.Y. Deutch The hallucinogen 1-[2, 5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) increases cortical extracellular glutamate levels in rats Neurosci. Lett. 346 2003 137 140
68. D.A. Wacker, and K.J. Miller Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple disease Curr. Opin Drug Discov. Devel. 11 2008 438 445
69. E.A. Walker, S.J. Kohut, R.W. Hass, E.K. Brown Jr., A. Prabandham, and T. Lefever Selective and nonselective serotonin antagonists block the aversive stimulus properties of MK212 and m-chlorophenylpiperazine (mCPP) in mice Neuropharmacology 49 2005 1210 1219
70. H. Weinstein Hallucinogen actions on 5-HT receptors reveal distinct mechanisms of activation and signaling by G protein-coupled receptors AAPS J. 7 2006 E871 E874
71. N.V. Weisstaub, M. Zhou, A. Lira, E. Lambe, J. González-Maeso, J.P. Hornung, E. Sibille, M. Underwood, S. Itohara, W.T. Dauer, M.S. Ansorge, E. Morelli, J.J. Mann, M. Toth, G. Aghajanian, S.C. Sealfon, R. Hen, and J.A. Gingrich Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice Science 313 2006 536 540
72. J.G. Wettstein, M. Host, and J.M. Hitchcock Selectivity of action of typical and atypical anti-psychotic drugs as antagonists of the behavioral effects of 1-[2, 5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) Prog. Neuropsychopharmacol. Biol. Psychiatry 23 1999 533 544
73. J.C. Winter, J.R. Eckler, and R.A. Rabin Serotonergic/glutamatergic interactions: the effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli Psychopharmacology (Berl) 172 2004 233 240
74. Y. Zhang, K.J. Damjanoska, G.A. Carrasco, B. Dudas, D.N. D'Souza, J. Tetzlaff, F. Garcia, N.R. Hanley, K. Scripathirathan, B.R. Petersen, T.S. Gray, G. Battaglia, N.A. Muma, and L.D. Van de Kar Evidence that 5-HT2A receptors in the hypothalamic paraventricular nucleus mediate neuroendocrine responses to (-)DOI J. Neurosci. 22 2002 9635 9642